Niquitin Sabor Menta (Nicotine)

Niquitin Sabor Menta is a nicotine replacement therapy used in the management of nicotine dependence and tobacco withdrawal.

• Smoking cessation: helps adult smokers reduce cravings and withdrawal symptoms while transitioning away from cigarettes.
• Tobacco use disorder: provides a controlled nicotine dose to support gradual reduction of tobacco consumption.
• Relapse prevention: assists individuals who have quit smoking to maintain abstinence by alleviating occasional urges.

• Nicotine acts as a partial agonist at neuronal nicotinic acetylcholine receptors (nAChRs) in the central nervous system. By stimulating these receptors, it releases dopamine and other neurotransmitters, producing mild stimulation that eases withdrawal. The controlled oromucosal delivery yields lower plasma nicotine peaks than smoking, thereby reducing the reinforcement of cigarette use while mitigating cravings. This pharmacological profile helps maintain a steady nicotine level, supporting the user’s effort to quit without the rapid spikes associated with smoking.

Common and serious adverse reactions have been reported with oromucosal nicotine products.

Common Side Effects

• Mouth irritation
• Nausea
• Headache
• Dizziness

Serious or Rare Side Effects

• Allergic reaction (rash, swelling, or anaphylaxis)
• Cardiovascular events (palpitations, hypertension, or arrhythmia)

Before using Niquitin Sabor Menta, consider the following precautions.

• Assess nicotine dependence before initiating therapy: determine baseline use and withdrawal risk.
• Do not use if allergic to nicotine or any excipients in the product.
• Monitor cardiovascular status in patients with known heart disease or hypertension.
• Avoid concurrent use of other nicotine‑containing products to prevent overdose.
• Store at room temperature: keep in the original packaging, protect from moisture and heat.

Niquitin Sabor Menta may interact with other medicines; review the following.

Major Interactions (Avoid)

• Concomitant use with other nicotine‑containing products: risk of nicotine overdose.
• Use with monoamine oxidase inhibitors (MAOIs): may increase hypertensive response.
• Use with beta‑blockers: nicotine‑induced tachycardia may be masked.

Moderate Interactions (Monitor Closely)

• CYP2A6 inhibitors (e.g., methoxsalen): may raise nicotine plasma levels.
• Alcohol consumption: can enhance nicotine’s cardiovascular effects.
• Caffeine intake: may increase incidence of headache and jitteriness.